Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Anesthesiology. 2020 Nov 1;133(5):1021–1028. doi: 10.1097/ALN.0000000000003529

Table 2.

Final Backward Elimination Models

Term Estimate [95% CI] P-value
Table 2a. Clinician Administered Dissociated States Score final model
Intercept −10.2 [−19.0, −1.3] 0.026
Midazolam [N] 10.3 [3.4, 17.1] 0.005
Time (min after ketamine) 0.6 [0.5, 0.8] <0.0001
Time (min after ketamine) x Time (min after ketamine) −0.004 [−0.01, −0.003 ] <0.0001
Table 2b. Pain intensity final model
Intercept 6.6 [5.7, 7.6] <0.0001
Time (min after ketamine) −0.1 [−0.1, −0.1] <0.0001
Time (min after ketamine) x Time (min after ketamine) 0.001 [0.001, 0.001] <0.0001
Table 2c. Nociceptive pain final model
Intercept 48.0 [43.0, 53.0] <0.0001
Time (min after ketamine) −0.3 [−0.4, −0.1] 0.0002
Time (min after ketamine) x Time (min after ketamine) 0.002 [0.001, 0.003] <0.0001
Table 2d. Neuropathic pain final model
Intercept 48.7 [45.6, 51.8] <0.0001
Time (min after ketamine) −0.1 [−0.2, −0.02] 0.015
Time (min after ketamine) x Time (min after ketamine) 0.001 [0.0001, 0.001] 0.024
Sex [F] −4.5 [−8.0, −1.0] 0.016

Estimate, unstandardized partial regression coefficient; for midazolam and sex, the estimate represents the difference in adjusted means; CI, confidence interval.